Spectacular margins of pharmaceutical companies on cancer in Switzerland (Swiss Press Online 2020, by Tybalt Félix) - Swiss Press Award

RTSinfo

Tybalt Félix

Cancer drug reimbursements are exploding in Switzerland, reaching a billion francs per year. Pharmaceutical companies cite completely opaque research costs to justify their prices. Our analysis of three treatments reveals a different story: the exceptional margins earned on molecules sold at exorbitant prices are severely impacting Swiss health insurance premiums.